Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenax Therapeutics

5.68
+0.01000.18%
Post-market: 5.680.00000.00%18:41 EDT
Volume:9.16K
Turnover:52.30K
Market Cap:22.52M
PE:-4.93
High:5.75
Open:5.75
Low:5.62
Close:5.67
Loading ...

Tenax Therapeutics Reports $10.4M Net Loss in Q1 2025, Up from $3.8M Loss in Q1 2024; R&D and G&A Expenses Surge

Reuters
·
10 hours ago

William Blair Remains a Buy on Tenax Therapeutics (TENX)

TIPRANKS
·
8 hours ago

Tenax Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
9 hours ago

Tenax Therapeutics Q1 EPS $(0.28) Misses $(0.19) Estimate

Benzinga
·
10 hours ago

Tenax Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
09 May

Tenax Therapeutics Advances Cardiopulmonary Therapies

TIPRANKS
·
25 Apr

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

TIPRANKS
·
16 Apr

Tenax Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
26 Mar

Tenax Therapeutics Q4 2024 GAAP EPS $(0.18) Beats $(0.42) Estimate

Benzinga
·
26 Mar

Tenax Therapeutics Inc: Qtrly Loss per Share $0.18

THOMSON REUTERS
·
26 Mar

Tenax Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview

Reuters
·
24 Mar

Tenax Therapeutics Inc : Leerink Partners Raises Target Price to $20 From $16

THOMSON REUTERS
·
10 Mar

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

TIPRANKS
·
06 Mar

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103

TIPRANKS
·
05 Mar

Tenax Therapeutics prices 378,346 shares at $6.04 in private placement

TIPRANKS
·
05 Mar

Tenax Therapeutics Announces $25 Million Private Placement

THOMSON REUTERS
·
05 Mar

Tenax Therapeutics: to Use Net Proceeds From Private Placement to Advance Ongoing & Planned Phase 3 Clinical Trials

THOMSON REUTERS
·
05 Mar

Tenax Therapeutics Announces $25 Million Private Placement

GlobeNewswire
·
05 Mar

Tenax Therapeutics Expands Phase 3 Level Program, Advancing Two Tnx-103 (Oral Levosimendan) Registrational Studies for the Treatment of Ph-Hfpef

THOMSON REUTERS
·
05 Mar

Tenax Therapeutics : Agreement by FDA to Initiate Second Global Phase 3 Study, Level-2, With First Patient Expected to Be Enrolled This Year

THOMSON REUTERS
·
05 Mar